The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pediatric Orphan Drugs Market Research Report 2024
Synopsis
Pediatric orphan drugs are medications that are specifically developed and approved for the treatment of rare diseases or conditions in children. These drugs are designed to address medical needs in pediatric populations who have limited treatment options due to the rarity of their conditions. Pediatric orphan drugs are vital in addressing the unique medical needs of children with rare diseases and improving their health outcomes and quality of life.
Global Pediatric Orphan Drugs market is projected to reach US$ 102180 million in 2029, increasing from US$ 51490 million in 2022, with the CAGR of 10.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pediatric Orphan Drugs market research.
According to our “ Pharma & Healthcare Research Center” statistics, the global sales of Orphan Drugs reached $139170 million in 2022. The North America region was the world largest Orphan Drugs market, accounting for 40% of Orphan Drugs sales in 2022, followed by Asia-Pacific. The global market for pediatric orphan drugs has been growing steadily in recent years due to increasing awareness of rare pediatric diseases, advancements in medical research and technology, and improved regulatory support for pediatric drug development.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pediatric Orphan Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Recordati SpA
Novartis
Celgene
Abbvie
Orpharma
Amgen
Amryt Pharma Plc.
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Pfizer
Sanofi
Takeda
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pediatric Orphan Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Pediatric orphan drugs are medications that are specifically developed and approved for the treatment of rare diseases or conditions in children. These drugs are designed to address medical needs in pediatric populations who have limited treatment options due to the rarity of their conditions. Pediatric orphan drugs are vital in addressing the unique medical needs of children with rare diseases and improving their health outcomes and quality of life.
Global Pediatric Orphan Drugs market is projected to reach US$ 102180 million in 2029, increasing from US$ 51490 million in 2022, with the CAGR of 10.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pediatric Orphan Drugs market research.
According to our “ Pharma & Healthcare Research Center” statistics, the global sales of Orphan Drugs reached $139170 million in 2022. The North America region was the world largest Orphan Drugs market, accounting for 40% of Orphan Drugs sales in 2022, followed by Asia-Pacific. The global market for pediatric orphan drugs has been growing steadily in recent years due to increasing awareness of rare pediatric diseases, advancements in medical research and technology, and improved regulatory support for pediatric drug development.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pediatric Orphan Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Recordati SpA
Novartis
Celgene
Abbvie
Orpharma
Amgen
Amryt Pharma Plc.
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Pfizer
Sanofi
Takeda
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pediatric Orphan Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pediatric Orphan Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oncology Drugs
1.2.3 Gastrointestinal Drugs
1.2.4 Neurology Drugs
1.2.5 Cardio-vascular Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Pediatric Orphan Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pediatric Orphan Drugs Market Perspective (2018-2029)
2.2 Pediatric Orphan Drugs Growth Trends by Region
2.2.1 Global Pediatric Orphan Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pediatric Orphan Drugs Historic Market Size by Region (2018-2023)
2.2.3 Pediatric Orphan Drugs Forecasted Market Size by Region (2024-2029)
2.3 Pediatric Orphan Drugs Market Dynamics
2.3.1 Pediatric Orphan Drugs Industry Trends
2.3.2 Pediatric Orphan Drugs Market Drivers
2.3.3 Pediatric Orphan Drugs Market Challenges
2.3.4 Pediatric Orphan Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pediatric Orphan Drugs Players by Revenue
3.1.1 Global Top Pediatric Orphan Drugs Players by Revenue (2018-2023)
3.1.2 Global Pediatric Orphan Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Pediatric Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pediatric Orphan Drugs Revenue
3.4 Global Pediatric Orphan Drugs Market Concentration Ratio
3.4.1 Global Pediatric Orphan Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pediatric Orphan Drugs Revenue in 2022
3.5 Pediatric Orphan Drugs Key Players Head office and Area Served
3.6 Key Players Pediatric Orphan Drugs Product Solution and Service
3.7 Date of Enter into Pediatric Orphan Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pediatric Orphan Drugs Breakdown Data by Type
4.1 Global Pediatric Orphan Drugs Historic Market Size by Type (2018-2023)
4.2 Global Pediatric Orphan Drugs Forecasted Market Size by Type (2024-2029)
5 Pediatric Orphan Drugs Breakdown Data by Application
5.1 Global Pediatric Orphan Drugs Historic Market Size by Application (2018-2023)
5.2 Global Pediatric Orphan Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pediatric Orphan Drugs Market Size (2018-2029)
6.2 North America Pediatric Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pediatric Orphan Drugs Market Size by Country (2018-2023)
6.4 North America Pediatric Orphan Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pediatric Orphan Drugs Market Size (2018-2029)
7.2 Europe Pediatric Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pediatric Orphan Drugs Market Size by Country (2018-2023)
7.4 Europe Pediatric Orphan Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pediatric Orphan Drugs Market Size (2018-2029)
8.2 Asia-Pacific Pediatric Orphan Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pediatric Orphan Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Pediatric Orphan Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pediatric Orphan Drugs Market Size (2018-2029)
9.2 Latin America Pediatric Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pediatric Orphan Drugs Market Size by Country (2018-2023)
9.4 Latin America Pediatric Orphan Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pediatric Orphan Drugs Market Size (2018-2029)
10.2 Middle East & Africa Pediatric Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pediatric Orphan Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Pediatric Orphan Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recordati SpA
11.1.1 Recordati SpA Company Detail
11.1.2 Recordati SpA Business Overview
11.1.3 Recordati SpA Pediatric Orphan Drugs Introduction
11.1.4 Recordati SpA Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.1.5 Recordati SpA Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Pediatric Orphan Drugs Introduction
11.2.4 Novartis Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Celgene
11.3.1 Celgene Company Detail
11.3.2 Celgene Business Overview
11.3.3 Celgene Pediatric Orphan Drugs Introduction
11.3.4 Celgene Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.3.5 Celgene Recent Development
11.4 Abbvie
11.4.1 Abbvie Company Detail
11.4.2 Abbvie Business Overview
11.4.3 Abbvie Pediatric Orphan Drugs Introduction
11.4.4 Abbvie Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.4.5 Abbvie Recent Development
11.5 Orpharma
11.5.1 Orpharma Company Detail
11.5.2 Orpharma Business Overview
11.5.3 Orpharma Pediatric Orphan Drugs Introduction
11.5.4 Orpharma Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.5.5 Orpharma Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Pediatric Orphan Drugs Introduction
11.6.4 Amgen Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Amryt Pharma Plc.
11.7.1 Amryt Pharma Plc. Company Detail
11.7.2 Amryt Pharma Plc. Business Overview
11.7.3 Amryt Pharma Plc. Pediatric Orphan Drugs Introduction
11.7.4 Amryt Pharma Plc. Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.7.5 Amryt Pharma Plc. Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Pediatric Orphan Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 GSK
11.9.1 GSK Company Detail
11.9.2 GSK Business Overview
11.9.3 GSK Pediatric Orphan Drugs Introduction
11.9.4 GSK Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.9.5 GSK Recent Development
11.10 Bristol-Myers Squibb Company
11.10.1 Bristol-Myers Squibb Company Company Detail
11.10.2 Bristol-Myers Squibb Company Business Overview
11.10.3 Bristol-Myers Squibb Company Pediatric Orphan Drugs Introduction
11.10.4 Bristol-Myers Squibb Company Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.10.5 Bristol-Myers Squibb Company Recent Development
11.11 Roche Holding
11.11.1 Roche Holding Company Detail
11.11.2 Roche Holding Business Overview
11.11.3 Roche Holding Pediatric Orphan Drugs Introduction
11.11.4 Roche Holding Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.11.5 Roche Holding Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Detail
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Pediatric Orphan Drugs Introduction
11.12.4 Pfizer Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.12.5 Pfizer Recent Development
11.13 Sanofi
11.13.1 Sanofi Company Detail
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Pediatric Orphan Drugs Introduction
11.13.4 Sanofi Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.13.5 Sanofi Recent Development
11.14 Takeda
11.14.1 Takeda Company Detail
11.14.2 Takeda Business Overview
11.14.3 Takeda Pediatric Orphan Drugs Introduction
11.14.4 Takeda Revenue in Pediatric Orphan Drugs Business (2018-2023)
11.14.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
